<DOC>
	<DOCNO>NCT01448616</DOCNO>
	<brief_summary>The investigator propose randomize , double blind , placebo-controlled , cross-over trial evaluate effect oral topical ( vaginal gel ) tenofovir genital herpes simplex virus ( HSV ) shed among herpes simplex virus type-2 ( HSV-2 ) seropositive , human immunodeficiency virus ( HIV ) seronegative woman . The investigator hypothesize tenofovir reduce genital HSV shed compare placebo .</brief_summary>
	<brief_title>Effect Tenofovir Genital Herpes Simplex Virus ( HSV ) Shedding</brief_title>
	<detailed_description>The investigator propose randomize , double-blind , placebo-controlled , cross-over study 55 adult , healthy woman HSV-2 seropositive HIV-1 seronegative . Women first participate run-in phase twice daily swab . Following 4 week swab , participant randomize 2:2:1 one three group : 1 ) oral tenofovir placebo gel , 2 ) oral placebo tenofovir gel , 3 ) oral placebo placebo gel . Participants begin treatment swab genital region twice daily 5 week . Study drug administer daily .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Women age 1850 HSV2 seropositive University Washington ( UW ) Western blot History recurrent genital herpes , 4 recurrence less 10 last year , currently suppressive therapy , 4 recurrence less 10 year prior start suppressive therapy HIV negative General good health Willing use antiviral therapy ( study drug ) duration study Willing obtain swab genital secretion twice daily duration study Willing use effective birth control Able provide write informed consent screen enrollment HIV positive high risk HIV acquisition ( intravenous drug user HIV+ sex partner ) Hepatitis B ( HepB ) antigen ( Ag ) positive , high risk HepB acquisition vaccinate Have history adverse reaction tenofovir and/or adefovir Immunosuppressive medication , except intranasal topical ( high potency ) steroid . Any kidney disease , renal insufficiency , define serum creatinine &gt; 1.5 mg/dl . Participants prior history single episode pyelonephritis eligible . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3 time upper limit normal Pregnancy , confirm urine pregnancy test , plan become pregnant course trial , breastfeed . Serious medical condition active infection Any condition judgment investigator would preclude successful completion clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>